Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental radioactive drug enters first human trials for tough cancers

NCT ID NCT07505771

Summary

This is a very early safety study testing a new radioactive cancer drug called 177Lu-IM-3050 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how the body handles the drug. Researchers will also check if the treatment shows any signs of shrinking tumors in these patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Excel Diagnostics and Nuclear Oncology Center

    Houston, Texas, 77042, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.